ARS Pharmaceuticals (SPRY) Accumulated Depreciation & Amortization: 2021-2024
Historic Accumulated Depreciation & Amortization for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2024 value amounting to -$79,000.
- ARS Pharmaceuticals' Accumulated Depreciation & Amortization fell 593.75% to -$79,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $198,000, marking a year-over-year decrease of 27.21%. This contributed to the annual value of $100,000 for FY2024, which is negligibly% changed negligibly from last year.
- Per ARS Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at -$79,000 for Q4 2024, which was down 179.00% from $100,000 recorded in Q3 2024.
- ARS Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $132,000 during Q1 2024, with a 5-year trough of -$79,000 in Q4 2024.
- For the 3-year period, ARS Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $57,556, with its median value being $68,000 (2023).
- As far as peak fluctuations go, ARS Pharmaceuticals' Accumulated Depreciation & Amortization spiked by 242.86% in 2022, and later tumbled by 593.75% in 2024.
- ARS Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $14,000 in 2021, then spiked by 242.86% to $48,000 in 2022, then plummeted by 66.67% to $16,000 in 2023, then slumped by 593.75% to -$79,000 in 2024.
- Its Accumulated Depreciation & Amortization stands at -$79,000 for Q4 2024, versus $100,000 for Q3 2024 and $45,000 for Q2 2024.